These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 24114790)

  • 1. Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor.
    Santoni M; Berardi R; Amantini C; Burattini L; Santini D; Santoni G; Cascinu S
    Int J Cancer; 2014 Jun; 134(12):2772-7. PubMed ID: 24114790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolving role of novel targeted agents in renal cell carcinoma.
    Hutson TE; Figlin RA
    Oncology (Williston Park); 2007 Sep; 21(10):1175-80; discussion 1184, 1187, 1190. PubMed ID: 17926797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Constitutional genetic variants as predictors of antiangiogenic therapy outcome in renal cell carcinoma.
    Rodríguez-Antona C; García-Donas J
    Pharmacogenomics; 2012 Nov; 13(14):1621-33. PubMed ID: 23148638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal treatment of poor-risk renal cell carcinoma patients with mTOR inhibitors and anti-VEGFR agents.
    Coinu A; Petrelli F; Barni S
    Expert Rev Anticancer Ther; 2016; 16(1):33-43. PubMed ID: 26535485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory T cells, dendritic cells and neutrophils in patients with renal cell carcinoma.
    Minárik I; Lašťovička J; Budinský V; Kayserová J; Spíšek R; Jarolím L; Fialová A; Babjuk M; Bartůňková J
    Immunol Lett; 2013 May; 152(2):144-50. PubMed ID: 23721909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel personalized vaccine approach in combination with targeted therapy in advanced renal cell carcinoma.
    Figlin RA
    Immunotherapy; 2014; 6(3):261-8. PubMed ID: 24354908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
    Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
    Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor.
    Park I; Lee JL; Ahn JH; Lee DH; Lee KH; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H
    Cancer Chemother Pharmacol; 2015 May; 75(5):1025-35. PubMed ID: 25776906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapies in the treatment of advanced renal cell carcinoma.
    Seront E; Machiels JP
    Recent Pat Anticancer Drug Discov; 2009 Jun; 4(2):146-56. PubMed ID: 19519537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosine kinase inhibitors reprogramming immunity in renal cell carcinoma: rethinking cancer immunotherapy.
    Aparicio LMA; Fernandez IP; Cassinello J
    Clin Transl Oncol; 2017 Oct; 19(10):1175-1182. PubMed ID: 28409322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications.
    Danesi R; Boni JP; Ravaud A
    Cancer Treat Rev; 2013 Nov; 39(7):784-92. PubMed ID: 23375248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Renal cell carcinoma].
    Tomita Y
    Gan To Kagaku Ryoho; 2014 Feb; 41(2):172-7. PubMed ID: 24743196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far.
    Tang PA; Vickers MM; Heng DY
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):871-91. PubMed ID: 21763972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
    Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
    Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting angiogenesis in renal cell carcinoma.
    Posadas EM; Limvorasak S; Sharma S; Figlin RA
    Expert Opin Pharmacother; 2013 Nov; 14(16):2221-36. PubMed ID: 23984807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of endothelial colony forming cells in kidney cancer's pathogenesis, and in resistance to anti-VEGFR agents and mTOR inhibitors: A speculative review.
    Poletto V; Rosti V; Biggiogera M; Guerra G; Moccia F; Porta C
    Crit Rev Oncol Hematol; 2018 Dec; 132():89-99. PubMed ID: 30447930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI?
    Calvo E; Ravaud A; Bellmunt J
    Cancer Treat Rev; 2013 Jun; 39(4):366-74. PubMed ID: 22832091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel treatment strategies in clear-cell metastatic renal cell carcinoma.
    van Spronsen DJ; de Weijer KJ; Mulders PF; De Mulder PH
    Anticancer Drugs; 2005 Aug; 16(7):709-17. PubMed ID: 16027518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pazopanib for the treatment of renal cancer.
    Al-Marrawi MY; Rini B
    Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapy for renal cell cancer: current perspectives.
    van der Veldt AA; Haanen JB; van den Eertwegh AJ; Boven E
    Discov Med; 2010 Nov; 10(54):394-405. PubMed ID: 21122471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.